ClinicalTrials.Veeva

Menu

Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness

Fudan University logo

Fudan University

Status

Not yet enrolling

Conditions

Colorectal Carcinoma
Liver Metastases

Treatments

Procedure: anatomical liver resection
Procedure: nonanatomical liver resection

Study type

Interventional

Funder types

Other

Identifiers

NCT05881746
ARCLAMP

Details and patient eligibility

About

In this study, colorectal cancer patients with initially resectable liver-only metastases, as prospectively confirmed by a local multidisciplinary team (MDT) according to predefined criteria, will be tested for RAS and BRAF tumor mutation status. Patients with gene mutant or right-sidedness will be randomised between anatomical resection (AR) or nonanatomical resection (NAR). The primary end-point is the relapse-free survival.

Full description

This study is a prospective, single-center, randomized control trial. The major including criteria are (1) Histologically confirmed colorectal cancer initially resectable liver-only metastases ; (2) patient has the opportunity to perform either anatomical resection (AR) or nonanatomical resection (NAR) surgery; (3) the number of metastasis is 1-3; (4) KRAS/NRAS/BRAF mutation or right-sidedness. Patients will be randomised between AR or NAR. Patients will be stratified for gene mutation and right-sidedness.

Based upon the segmental anatomy of the liver according to Couinaud system, AR is defined as the resection of one or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination thereof. NAR, also called as wedge resection, is defined as the resection of the tumor with a margin of normal parenchyma regardless of the hepatic anatomy.

The primary end-point is the relapse-free survival. The secondary end-points are postoperative complication, postoperative mortality, hospital length of stay, and overall survival.

Enrollment

176 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 and ≤ 75 years;
  2. Histological proof of colorectal adenocarcinoma;
  3. Resectable colorectal liver metastasis without detectable extrahepatic distant metastatic disease (determined by a local MDT);
  4. Suitable for anatomical or nonanatomical liver resection (determined by a local MDT);
  5. Number of metastasis is 1 to 3;
  6. KRAS/NRAS/BRAF mutation or right-sidedness;
  7. Performance Status (ECOG) 0~1;
  8. Adequate hematological function: Neutrophils≥1.5 x109/l and platelet count≥100 x109/l; Hb ≥9g/dl (within 1 week prior to randomization);
  9. Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, serum transaminases ≤ 5x upper limit of normal(ULN), and serum creatinine ≤ 1.5x ULN and creatinine clearance ≥ 30 ml/min;
  10. Written informed consent.

Exclusion criteria

  1. Previous systemic treatment for metastatic disease;
  2. Previous surgery for metastatic disease;
  3. Extrahepatic metastases;
  4. Unresectable primary tumor;
  5. Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, CVA) within 12 months before randomisation;
  6. Second primary malignancy within the past 5 years;
  7. Acute or subacute intestinal obstruction;
  8. Drug or alcohol abuse;
  9. No legal capacity or limited legal capacity;
  10. Pregnant or lactating women.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

176 participants in 2 patient groups

anatomical resection group
Experimental group
Description:
Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) is defined as the resection of one or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination thereof.
Treatment:
Procedure: anatomical liver resection
nonanatomical resection group
Active Comparator group
Description:
nonanatomical resection (NAR), also called as wedge resection, is defined as the resection of the tumor with a margin of normal parenchyma regardless of the hepatic anatomy.
Treatment:
Procedure: nonanatomical liver resection

Trial contacts and locations

1

Loading...

Central trial contact

Jianmin Xu, MD; Yijiao Chen, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems